Abstract: Described herein are compositions and methods useful for allowing for the absorption (passage) of agents of interest, such as therapeutic agents, across epithelial and mucosal barriers and/or into certain subcellular compartments of the cell, such as the recycling endosome (RE), Golgi, and the endoplasmic reticulum (ER).
Type:
Grant
Filed:
September 4, 2009
Date of Patent:
October 4, 2016
Assignee:
Children's Medical Corporation
Inventors:
Wayne I. Lencer, Daniel J F Chinnapen, Randy Mrsny
Abstract: The invention provides new and useful analogs of 2-phthalimidinoglutaric acid. These analogs include DL-2-methyl-2-phthalimidinoglutaric acid and hydroxylated analogs of 2-phthalimidinoglutaric. The invention also provides processes for making these analogs. The invention also provides the two individual enantiomers of DL-2-methyl-2-phthalimidinoglutaric acid, (R) (+)-2-methyl-2-phthalimidinoglutaric acid and (S)-(−)-2-methyl-2-phthalimidinoglutaric acid, and processes for separating these individual enantiomers from the racemate. Further, the invention provides methods for inhibiting angiogenesis and treating angiogenesis-associated diseases, including cancer and macular degeneration, by administering one or more of these compounds.
Type:
Application
Filed:
December 9, 2003
Publication date:
July 1, 2004
Applicant:
Childrens' Medical Corporation
Inventors:
Robert J. D'Amato, Shawn J. Green, John W. Madsen, William Fogler, Glenn M. Swartz, Adonia E. Papathanassiu, Jamshed H. Shah